Pfizer signs deal to cover open-access publication costs

Pharmaceutical company Pfizer has signed a membership agreement with BioMed Central to cover publication costs for research articles published by its researchers.

The deal means that Pfizer will centrally cover the publication fees for any researcher employed or funded by Pfizer when they submit a research article to one of BioMed Central’s open-access journals. Pfizer aims to make it as straightforward as possible for its researchers to make their research results universally accessible.

Matthew Cockerill, BioMed Central’s managing director, commented, ‘This new agreement between BioMed Central and Pfizer demonstrates that the pharmaceutical industry also recognises the benefits of open access.’